Articles tagged with Breast Cancer
A 15-year follow-up of over 1000 DCIS patients found that radiotherapy reduced local recurrence risk by 50%, while improving survival for invasive recurrence cases. The study suggests a continuous protective effect of RT on DCIS recurrence in the long term.
A national survey of OB-GYNs found that most doctors do not routinely ask about sexual problems or satisfaction, and even fewer inquire about a patient's orientation. This omission can lead to missed opportunities for diagnosis and treatment, with women often suffering in silence due to fear or embarrassment.
Researchers found that cognitive behavioural therapy (CBT) and physical exercise can significantly reduce menopausal symptoms, such as hot flushes and vaginal dryness, in breast cancer patients undergoing treatment. The interventions also improved sexuality and physical functioning, with positive effects still apparent after six months.
A new genomic test has been shown to help doctors identify breast cancer patients who do not need adjuvant chemotherapy, reducing side effects and improving quality of life. The study found that patients classified as low risk by the test had a higher distant disease-free survival rate compared to those classified as high risk.
A Dutch study reveals that breast cancer screening and improved treatments together save a significant number of lives. The study found that adjuvant therapy reduced deaths by 13.9%, while two-yearly screening added another 15.7%. Combining both approaches resulted in a total reduction of 31.1% in breast cancer mortality.
A stress management program for breast cancer patients can alter tumor-promoting processes at the molecular level, facilitating better recovery during treatment. The study found that women who participated in the program had improved psychological adaptation and physiological changes indicating better recovery.
A 20-year breast cancer screening program in the Netherlands showed a significant drop in deaths from the disease, with a 31% reduction in deaths among women aged 55-79. The program also found limited harm from false positives and over-diagnosis, with only 2.8% of all breast cancers diagnosed being over-diagnosed.
A recent study suggests that MRI screening could be a cost-effective option for women with a familial risk of breast cancer, despite being expensive. The research found that adding MRI to standard mammography screening reduces deaths by 24% at a lower cost per year of life gained.
Research presented at the European Breast Cancer Conference found that women with denser breasts have a nearly double risk of local recurrence. The study, which involved 1,774 post-menopausal women, highlights the importance of considering breast density in treatment decisions and follow-up routines.
Researchers have identified obscurins as tumor suppressor genes in the breast, which are lost or mutated when cancer develops. This discovery holds promise for developing new tools to assess breast cancer risk and diagnose it at an early stage.
Detecting circulating tumour cells in blood can provide information about breast cancer survival and help target treatment. Patients with high CTC counts have a higher risk of recurrence and death, while CTC detection may also become a target for future therapy.
New research shows that becoming pregnant after a diagnosis of estrogen receptor positive breast cancer does not increase the risk of recurrence. In fact, patients who become pregnant appear to survive longer than those who do not. The study also found no difference in disease-free survival between women with ER+ or ER- disease.
Researchers have discovered a new growth-driving protein, MYC, that drives the growth of aggressive triple-negative breast tumors. Blocking a cooperating protein, CDK, causes these tumors to regress in mice, offering a potential new target for treatment.
The RESTORE-2 trial found high rates of investigator and patient satisfaction with autologous adipose-derived regenerative cell (ADRC)-enriched fat grafting for breast reconstruction after cancer surgery. The procedure also showed improved breast contour and no local cancer recurrences or serious adverse events.
A recent review of large prospective cohort studies and WHI trials found that estrogen plus progestin increases breast cancer risk, while estrogen alone decreases risk in women with a previous hysterectomy. The study proposes that mammography screening differences may explain the observed effects.
New monoclonal antibody drugs are being tested in most tumor types, allowing them to bind to multiple targets and stimulate the immune response. Researchers have developed advanced antibody engineering techniques to create more effective treatments, including bispecific antibodies and conjugates with toxic payloads.
A recent study published in Cancer Research suggests that dietary cadmium may be associated with an increased risk of breast cancer. Women who consumed higher amounts of whole grain and vegetables had a lower risk of breast cancer compared to those exposed through other foods.
A recent study published in the Journal of The National Cancer Institute suggests that estrogen alone may reduce breast cancer risk, whereas estrogen plus progestin can increase it. The findings are based on data from two randomized clinical trials conducted as part of the Women's Health Initiative.
Researchers at Thomas Jefferson University have discovered a powerful new strategy for personalized anti-cancer therapy by linking biomarker MCT4 to tumor metabolism. High levels of MCT4 are correlated with poorer overall survival and increased risk of recurrence in patients with triple negative breast cancer.
A recent study found that Asian breast cancer patients suffer from memory loss, decision-making difficulties, and speech problems after chemotherapy treatment. To cope with these changes, many turned to mind stimulation activities such as mahjong and qi gong.
Researchers at the University of Kentucky have identified a key protein interaction that promotes metastasis in triple-negative breast cancer. Snail interacts with G9a to suppress E-cadherin expression, which is critical for cell adhesion and preventing tumor spread.
Researchers have identified a critical link in the signaling pathway that enables cancer cells to establish tumors in distant parts of the body. A new drug targeting this molecule may help prevent cancer from spreading, offering hope for improved treatment options.
Researchers at Rensselaer Polytechnic Institute found a previously unknown link between breast cancer cells and the stroma. Cadherin-23, a new molecule, helps connect cancerous tumor cells to healthy tissue, facilitating invasive growth.
A study found that bone marrow-derived progenitor cells promote liver regeneration in rats, improving our understanding of how liver tissue can regenerate following damage. Researchers also discovered a new determinant of human breast cancer metastasis, highlighting the potential for new therapeutics targeting this pathway.
A new study published in The Lancet Oncology found that estrogen-only form of menopausal hormone therapy continues to protect women from breast cancer, with a 23% reduced incidence and 63% lower mortality rate compared to placebo. The research followed over 7,500 women for nearly 12 years.
Breast imaging tests have been shown to be ineffective in improving patient outcomes and healthcare quality for women with breast pain. The study analyzed over 900 cases, revealing that these tests did not provide significant reassurance or diagnostic value.
Researchers at Purdue University have developed a new imaging technique to detect subtle changes in breast tissue, which may help determine a woman's risk of developing breast cancer. The technology uses vibrational spectral microscopy to identify early precancerous stages and study the impact of fatty acids on breast tissue.
Researchers will focus on inhibiting cancer cell metabolism by targeting Mct1 and Mct4 proteins, which transport lactic acid out of cancer cells. The goal is to develop broad-spectrum anti-cancer therapeutics for breast cancer and lymphoma.
Women who used estrogen-only hormone replacement therapy (HRT) are less likely to develop breast cancer and die from the disease compared to those who never used HRT. The study, based on data from over 7,500 women, found a 23% reduction in breast cancer incidence and a 63% reduction in deaths from the disease.
Scientists at Max Planck Institute for Heart and Lung Research found that blocking Plexin B1 can prevent the formation of breast cancer metastases in mice. The study suggests a new potential approach to improving prognosis for patients with aggressive breast cancer.
A case-control study found that injectable and oral contraceptives are associated with a transiently increased risk of breast and cervical cancer. Extended use, however, is linked to a reduced risk of ovarian and endometrial cancer in black South African women.
Two studies found that CYP2D6 genotypes associated with reduced enzyme activity do not predict clinical responsiveness to adjuvant tamoxifen therapy among postmenopausal women. This challenges the conventional hypothesis that poor metabolizers experience fewer side effects and may receive less benefit from tamoxifen.
A large clinical trial found radiation has little benefit for some older women with early stage, low-risk breast cancer, leading to changes in treatment guidelines. However, the use of radiation therapy among Medicare beneficiaries remained largely unchanged, suggesting minimal impact on clinician practice.
Scientists discover Plexin-B1 as a potential therapeutic target for ErbB-2-overexpressing breast cancers, which have high metastatic potential. Additionally, researchers find that blocking the ErbB-2/Plexin-B1 interaction may reduce the risk of metastasis in patients with this type of cancer. In another study, researchers identify a be...
Researchers have found that Plexin-B1 represents a new candidate therapeutic target to treat patients with breast cancer found to overexpress the molecule ErbB-2. Overexpression of ErbB-2 led to activation of Plexin-B1, promoting metastatic cell characteristics in human breast cancer cells and reducing prognosis in human patients.
Researchers find that loss of STAT1 protein leads to increased breast cancer development in mice, as the immune system loses ability to control tumors. This discovery suggests that STAT1 may play a crucial role in preventing unwanted cell division and tumor growth.
A recent study published in Cancer Epidemiology, Biomarkers, & Prevention suggests that stopping hormone therapy can lead to tumor regression and decline new breast cancer rates. Researchers analyzed data from over 741,000 woman-years, finding no correlation between screening mammography use and former hormone users
A study by Vall d'Hebron Institute of Oncology reveals a potential new strategy to boost efficacy and break down resistance in patients with HER2 positive breast cancer. The combination of two drugs shows promise as a third treatment option, offering hope for patients with advanced tumours.
A study published in the Journal of Clinical Oncology found that women who underwent chemotherapy with the CMF regimen between 1976 and 1995 scored slightly lower on cognitive tests compared to those without a history of cancer. The differences were subtle but statistically significant, affecting word learning, memory, and information ...
Scientists at UCSF found simultaneous targeting of two molecules can effectively shrink tumors, block invasion, and stop metastasis in mice. The approach may improve combination treatments, including drugs like Avastin, for various cancer types.
A survey of over 41,000 patients with various cancers found that women, young people, and ethnic minorities experience delayed recognition due to symptom characteristics. GPs are less likely to consider cancer in younger patients and those from different ethnic groups, leading to longer consultation times.
A recent study published in Radiology found that mammography-detected breast cancers in women between the ages of 40 and 49 have a significantly better prognosis compared to non-mammography detected cases. This is attributed to earlier detection and treatment, resulting in lower recurrence rates and mortality.
A new study has identified a mutation in the Abraxas gene as a potential contributor to breast cancer susceptibility. The Abraxas protein interacts with BRCA1 and its mutation impairs DNA repair, increasing cancer risk.
Researchers at Weill Cornell Medical College found that a single protein, versican, is key to reversing the process of cancer metastasis in breast cancer. When versican was stopped from functioning, breast cancer could not seed itself into the lungs and form secondary tumors.
The USP15 protein has been identified as a critical regulator of cancer progression and immune response, accelerating drug development against glioblastoma and other types of cancer. USP15 promotes tumor growth by activating the TGFβ pathway, but its inhibition can lead to decreased TGFβ activity and reduced tumor development.
Researchers found that breast cancers can hijack an embryonic program to promote tumor growth and survival. A new study details how this 'on-off' switch is flipped by a protein called SIX1, which allows doctors to delete the pathway when it promotes tumors.
A new study published in The Lancet Oncology shows that cognitive behavioural therapy (CBT) significantly reduces hot flushes and night sweats in women after breast cancer treatment. CBT improves symptoms by 46-52% compared to usual care, with sustained benefits at 26 weeks.
A new study found people with Lynch syndrome have an increased risk of developing several types of cancer, including bowel, uterus, ovarian, kidney, stomach, and bladder cancers. The study also revealed a moderately increased risk of breast and pancreatic cancer in those with the condition.
The study identified biologically relevant targets in breast cancer using mRNA sequencing, revealing novel and unannotated transcripts. The GW research team discovered common and differentially expressing transcripts between three types of breast cancer, shedding light on the disease's underlying mechanisms.
A study published in the American Journal of Physical Medicine and Rehabilitation found that breast cancer patients undergo increased activation of neck and shoulder muscles during upper limb tasks, potentially leading to chronic pain.
Researchers at UCLA's Jonsson Comprehensive Cancer Center found that radiation treatment converts normal breast cancer cells into treatment-resistant stem cells. These induced breast cancer stem cells have a 30-fold increased ability to form tumors, undermining the effectiveness of radiation therapy.
Researchers at Stanford University have identified a sequential treatment regimen that enhances the effectiveness of trastuzumab in xenotransplant models of breast cancer. Trastuzumab activates natural killer cells to kill HER2-overexpressing tumor cells.
A prospective study links Lynch syndrome with significantly increased risks of breast and pancreatic cancers, while relatives without genetic mutations have no increased risk. The study provides clearer estimates of cancer risks associated with Lynch syndrome and may inform screening and early detection strategies.
A study found that children born to mothers who received chemotherapy during pregnancy have normal cognitive development and no significant differences in behavior, health, or hearing compared to the general population. However, premature birth was associated with lower cognitive scores.
Breast cancer in pregnant women is common and treatable with surgery or chemotherapy. A normal-length pregnancy should be the aim to avoid premature birth. Chemotherapy can be given as per standard guidelines, but radiation therapy is not advised due to fetal shielding concerns.
Researchers at Wake Forest Baptist Medical Center have developed a nanotube therapy that kills breast cancer stem cells by generating heat using laser treatment. The approach has shown promise in eliminating both differentiated cells and cancer stem cells, offering new hope for a cure.
Increasing age is associated with a higher risk of death from breast cancer in postmenopausal women, particularly those over 75 years old. The study found that disease-specific mortality increases with age, even after accounting for other factors, suggesting possible undertreatment as an underlying mechanism.
Researchers found striking similarities between genetic signatures of human breast cancer and those of stem cells in mouse embryos, revealing a new way to predict and personalize cancer therapies. The discovery could lead to the development of targeted treatments for aggressive forms of triple-negative breast cancer.
Researchers at Kimmel Cancer Center found that cyclin D1 overexpression associates with chromosomal instability in luminal B breast cancer. Elevated levels of cyclin D1 promote genetic breakdown known as chromosomal instability, which correlates with this subtype.
A new study reveals that women born to older mothers and taller, thinner girls before puberty are more likely to develop breast cancer. The research suggests that accumulated exposure to hormones during early life influences breast tissue composition and tumour development.